{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:28:06Z","timestamp":1790483286167,"version":"4.1.0"},"reference-count":44,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2017,2,14]]},"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Today's highly efficacious, low-toxicity interferon-free treatment regimens for chronic hepatitis C virus (HCV) can cure most patients with HCV in 12\u201324\u2005weeks. The aim of this study was to understand how the introduction of shorter duration treatment regimens for HCV will impact the capacity for treatment and value to society.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A Markov model of HCV transmission and progression was constructed, incorporating nationally representative data on HCV prevalence, incidence and progression; mortality, treatment costs, medical expenditures, employment probabilities and disability payments in Germany. The model was stratified by HCV genotype and exposure route (1-time healthcare exposure, injection drug use and sexual activity). Treatment scenarios were based on German treatment guidelines and projected treatment capacity. The impact of different treatment scenarios on disease transmission and prevalence, quality-adjusted life years (QALYs), treatment costs, medical expenditures, employment and disability expenditures was calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Depending on their adoption profile, new treatment regimens and protocols introduced over the next several years will increase HCV treatment capacity in Germany by 8\u201330%, reducing disease transmission and prevalence, increasing QALYs and adding \u20ac94\u2013310 million in discounted social value (QALYs plus medical savings net of treatment costs) over a 30-year horizon. Additional social value in the form of higher employment and lower disability would also result.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The introduction of shorter HCV treatment regimens and the resulting increased treatment capacity in Germany would result in large gains to society by reducing disease transmission and prevalence, resulting in longer, healthier, more productive lives for current and future generations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2016-000130","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T15:46:13Z","timestamp":1491320773000},"page":"e000130","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Economic study of the value of expanding HCV treatment capacity in Germany"],"prefix":"10.1136","volume":"4","author":[{"given":"Urbano","family":"Sbarigia","sequence":"first","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wirth","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Van Nuys","sequence":"additional","affiliation":[{"name":"Precision Health Economics, Los Angeles, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Huber","sequence":"additional","affiliation":[{"name":"Precision Health Economics, Los Angeles, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Brookmeyer","sequence":"additional","affiliation":[{"name":"UCLA Fielding School of Public Health, Los Angeles, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jona","family":"Stahmeyer","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Krauth","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"2025073012503967000_4.1.e000130.1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i5.725"},{"key":"2025073012503967000_4.1.e000130.2","unstructured":"World Health Organization. Draft global health sector strategy on viral hepatitis, 2016\u20132021 \u2013 the first of its kind. 2015. http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/Draft_global_health_sector_strategy_viral_hepatitis_13nov.pdf (accessed 5 Dec 2016)."},{"key":"2025073012503967000_4.1.e000130.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1400160"},{"key":"2025073012503967000_4.1.e000130.4","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.1193"},{"key":"2025073012503967000_4.1.e000130.5","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12249"},{"key":"2025073012503967000_4.1.e000130.6","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000062"},{"key":"2025073012503967000_4.1.e000130.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"2025073012503967000_4.1.e000130.8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jvh.12422","article-title":"Interferon-free, direct-acting antiviral therapy for chronic hepatitis C","volume":"22","author":"Gutierrez","year":"2015","journal-title":"J Viral Hepat"},{"key":"2025073012503967000_4.1.e000130.9","unstructured":"Robert Koch Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2014. In: Gilsdorf A, ed. Berlin, 2015. http:\/\/edoc.rki.de\/series\/infektionsepidemiologische-jahrbuecher\/2015\/PDF\/infektionsepidemiologischesjahrbuch-meldepflicht.pdf (accessed 5 Dec 2016)."},{"key":"2025073012503967000_4.1.e000130.10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12879-015-1048-z","article-title":"Cost-effectiveness of interferon-free therapy for hepatitis C in Germany\u2014an application of the efficiency frontier approach","volume":"15","author":"Gissel","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025073012503967000_4.1.e000130.11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.36469\/9870","article-title":"Cost-effectiveness of triple therapy with telaprevir for chronic hepatitis C virus patients in Germany","volume":"1","author":"Stahmeyer","year":"2013","journal-title":"J Health Econ Outcomes Res"},{"key":"2025073012503967000_4.1.e000130.12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20974"},{"key":"2025073012503967000_4.1.e000130.13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360724"},{"key":"2025073012503967000_4.1.e000130.14","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0095"},{"key":"2025073012503967000_4.1.e000130.15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-2007-963691","article-title":"[Epidemiology of chronic hepatitis C in Germany\u2014an analysis of 10,326 patients in hepatitis centres and outpatient units]","volume":"46","author":"H\u00fcppe","year":"2008","journal-title":"Z Gastroenterol"},{"key":"2025073012503967000_4.1.e000130.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.011"},{"key":"2025073012503967000_4.1.e000130.17","unstructured":"Paul-Ehrlich-Institut. Ten years of responsibility of PEI for blood and blood products 2006 http:\/\/www.pei.de\/EN\/institute\/who-collaborating-centres\/who-collaborating-centre-blood-ivd\/blood-products\/who-ten-years-responsibility-pei-chronological-overview.html"},{"key":"2025073012503967000_4.1.e000130.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61311-2"},{"key":"2025073012503967000_4.1.e000130.19","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000834"},{"key":"2025073012503967000_4.1.e000130.20","unstructured":"Incidence, Genotype Distribution, and Prognosis of Sexually Transmitted Acute Hepatitis C in a Cohort of HIV-infected Patients. 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) San Francisco, USA, 2010."},{"key":"2025073012503967000_4.1.e000130.21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/MEG.0000000000000181","article-title":"Cost of treating hepatitis C in Germany: a retrospective multicenter analysis","volume":"26","author":"Stahmeyer","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025073012503967000_4.1.e000130.22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1468-1293.2012.01005.x","article-title":"Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics","volume":"13","author":"Dirks","year":"2012","journal-title":"HIV Med"},{"key":"2025073012503967000_4.1.e000130.23","unstructured":"Federal Statistical Office of Germany. Statistical yearbook. Wiesbaden, 2012. https:\/\/www.destatis.de\/EN\/Publications\/Specialized\/Population\/StatYearbook_Chapter2_5011001129004.pdf?__blob=publicationFile (accessed 5 Dec 2016)."},{"key":"2025073012503967000_4.1.e000130.24","unstructured":"Organization for Economic Co-operation and Development. Labour Force Survey by Age and Sex. OECDstat, 2014."},{"key":"2025073012503967000_4.1.e000130.25","unstructured":"Federal Statistical Office. Population depending on sex and age (age classes of relevance to infrastructure) 2011. https:\/\/ergebnisse.zensus2011.de\/?locale=en#StaticContent:00,BEG_1_1_2,m,table"},{"key":"2025073012503967000_4.1.e000130.26","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12247"},{"key":"2025073012503967000_4.1.e000130.27","unstructured":"Kollan C , Schmidt D , Bartmeyer B , et al . How many patients treated? The number of patients with statutory health insurance receiving antiviral hepatitis C therapy determined with drug prescription data. Deutsch-\u00d6sterreichischer Aids-Kongress: D\u00d6AK 2015 Abstractband, 2015;7:15."},{"key":"2025073012503967000_4.1.e000130.28","unstructured":"IHS I. German pharma market grows 6% y\/y in H1, SPD health expert accuses cancer-drug producers of \u201cabusing market power\u201d. In: IHS I, ed. 2015. https:\/\/www.ihs.com\/country-industry-forecasting.html?ID=10659105440 (accessed 5 Dec 2016)."},{"key":"2025073012503967000_4.1.e000130.29","unstructured":"Berg T , Herder J , Krauth C , et al . The Eco-Hep Report: A macroeconomic overview of viral hepatitis C in Germany, 2016. https:\/\/www.leberhilfe-projekt.de\/files\/Projekte\/Hepatitis-C-Belastung-in-Deutschland\/downloads\/Eco-Hep-Report-GERMAN.pdf (accessed 5 Dec 2016)."},{"key":"2025073012503967000_4.1.e000130.30","unstructured":"Merck. Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir\/Elbasvir at the International Liver CongressTM 2015. Kenilworth, NJ, 2015."},{"key":"2025073012503967000_4.1.e000130.31","unstructured":"Gilead Sciences I. Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C. 2015. http:\/\/www.gilead.com\/news\/press-releases\/2015\/4\/gilead-announces-data-for-investigational-alloral-pangenotypic-threedrug-regimen-of-sofosbuvir-gs5816-and-gs9857-for-chronic-hepatitis-c (accessed 5 Dec 2016)."},{"key":"2025073012503967000_4.1.e000130.32","unstructured":"Janssen Pharmaceuticals. Janssen Enters into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. to Combat Hepatitis C Virus , 2015. http:\/\/www.investor.jnj.com\/releasedetail.cfm?releaseid=913984 (accessed 5 Dec 2016)."},{"key":"2025073012503967000_4.1.e000130.33","unstructured":"Sofosbuvir\/GS-5816+ GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-infected Patients. Oral session presented at the Liver Meeting of the American Association for the Study of Liver Diseases; 2015. Wiley Online Library."},{"key":"2025073012503967000_4.1.e000130.34","unstructured":"Institute for Quality and Efficiency in Health Care. General Methods: Version 4.2, 2015 http:\/\/www.iqwig.de\/download\/IQWiG_General_Methods_Version_%204-2.pdf"},{"key":"2025073012503967000_4.1.e000130.35","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0b013e3182a78fd8"},{"key":"2025073012503967000_4.1.e000130.36","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/ijerph7041835","article-title":"Health economic assessment: cost-effectiveness thresholds and other decision criteria","volume":"7","author":"Simoens","year":"2010","journal-title":"Int J Environ Res Public Health"},{"key":"2025073012503967000_4.1.e000130.37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00103-013-1673-x","article-title":"[Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]","volume":"56","author":"Poethko-M\u00fcller","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2025073012503967000_4.1.e000130.38","doi-asserted-by":"crossref","first-page":"KG148","DOI":"10.1055\/s-0035-1559174","article-title":"The impact of LDV\/SOF treatment on the work productivity of patients with chronic hepatitis C in Germany","volume":"53","author":"Mauss","year":"2015","journal-title":"Z Gastroenterol"},{"key":"2025073012503967000_4.1.e000130.39","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12483"},{"key":"2025073012503967000_4.1.e000130.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.052"},{"key":"2025073012503967000_4.1.e000130.41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055285"},{"key":"2025073012503967000_4.1.e000130.42","doi-asserted-by":"crossref","unstructured":"Buggisch P , Sarrazin C , Mauss S , et al . P0777: Sofosbuvir-based treatment under real life conditions in Germany (The sofger trial). J Hepatol 62:S622.","DOI":"10.1016\/S0168-8278(15)30980-6"},{"key":"2025073012503967000_4.1.e000130.43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/s-0034-1399383","article-title":"Real-life experience with first generation HCV protease inhibitor therapy in Germany: the prospective, non-interventional PAN cohort","volume":"53","author":"Mauss","year":"2015","journal-title":"Z Gastroenterol"},{"key":"2025073012503967000_4.1.e000130.44","first-page":"SP205","article-title":"Real-world outcomes of ledipasvir\/sofosbuvir in treatment-naive patients with hepatitis C","volume":"22","author":"Younossi","year":"2016","journal-title":"Am J Manag Care"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2016-000130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:50:52Z","timestamp":1753905052000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2016-000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,1]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1136\/bmjgast-2016-000130"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2016-000130","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}